Medidata's Solutions Selected by Mesoblast Limited
Medidata Solutions (MDSO), a provider of cloud-based clinical development solutions, recently announced that its Medidata Rave solution, including Rave Safety Gateway (News
), Rave Targeted SDV, and Medidata Coder, have been selected
by Mesoblast Limited, a company that develops biologic products for the broad field of regenerative medicine. The solutions will help Mesoblast support the development of treatments based on its proprietary adult stem cell technology.
Medidata Rave is a system for capturing, managing and reporting clinical research data, designed to help life science companies optimize their research investments by efficiently streamlining the clinical trial process. It has the flexible design to support the breadth of any organization's clinical processes, as well as the unique aspects of individual clinical trials. Medidata Rave provides industry-leading electronic data capture and clinical data management, user-configurable work flows, sophisticated eCRF design, simple and complex edit checking, customizable security parameters and integrations of other data sources.
On the other hand, Rave Safety Gateway is a secure, configurable EDC-to-safety-system interface that enhances Medidata Rave EDC with adverse event (AE) and serious adverse event (SAE) collection and E2B transmission capabilities. With Safety Gateway, sponsors can greatly improve the accuracy and speed of safety data collection and transfer to safety systems, yielding significant savings in time and resources. Moreover, Rave Targeted SDV provides research sponsors and CROs with an EDC-based, scalable and auditable solution to execute partial (less than 100 percent) SDV strategies and enables compliance with their regulatory framework.
"Mesoblast chose Medidata Solutions for our ability to drive improved efficiency and more effective decision making across their trials process," said Tarek Sherif, CEO, Medidata Solutions. "We're very excited that the Medidata Clinical Cloud is playing a key role in allowing Mesoblast to execute at the forefront of regenerative medicine research and adult stem cell technology."
Edited by Brooke Neuman
[ Back To TMCnet.com's Homepage ]